Published in Am J Gastroenterol on May 24, 2011
Study of A3309 in Patients With Chronic Idiopathic Constipation (ACCESS) | NCT01007123
American Gastroenterological Association technical review on constipation. Gastroenterology (2013) 3.27
Increased bile acid biosynthesis is associated with irritable bowel syndrome with diarrhea. Clin Gastroenterol Hepatol (2012) 2.13
The solute carrier family 10 (SLC10): beyond bile acid transport. Mol Aspects Med (2013) 1.11
Non-systemic drugs: a critical review. Curr Pharm Des (2012) 1.02
Agents that act luminally to treat diarrhoea and constipation. Nat Rev Gastroenterol Hepatol (2012) 0.99
Sodium-dependent bile salt transporters of the SLC10A transporter family: more than solute transporters. Pflugers Arch (2013) 0.97
Brain-gut axis: from basic understanding to treatment of IBS and related disorders. J Pediatr Gastroenterol Nutr (2012) 0.96
Underlying molecular and cellular mechanisms in childhood irritable bowel syndrome. Mol Cell Pediatr (2016) 0.94
Evolution of substrate specificity for the bile salt transporter ASBT (SLC10A2). J Lipid Res (2012) 0.91
New and Emerging Treatment Options for Irritable Bowel Syndrome. Gastroenterol Hepatol (N Y) (2015) 0.91
Therapeutic targeting of bile acids. Am J Physiol Gastrointest Liver Physiol (2015) 0.91
Emerging Pharmacologic Therapies for Constipation-predominant Irritable Bowel Syndrome and Chronic Constipation. J Neurogastroenterol Motil (2014) 0.88
Constipation-predominant irritable bowel syndrome: a review of current and emerging drug therapies. World J Gastroenterol (2014) 0.86
Drug pipeline is flush with new options for chronic constipation. Nat Med (2012) 0.86
Pharmacological agents currently in clinical trials for disorders in neurogastroenterology. J Clin Invest (2013) 0.83
Understanding and treating refractory constipation. World J Gastrointest Pharmacol Ther (2014) 0.79
Elobixibat and its potential role in chronic idiopathic constipation. Therap Adv Gastroenterol (2014) 0.78
Chronic Constipation and Constipation-Predominant IBS: Separate and Distinct Disorders or a Spectrum of Disease? Gastroenterol Hepatol (N Y) (2016) 0.77
c-Fos mediates repression of the apical sodium-dependent bile acid transporter by fibroblast growth factor-19 in mice. Am J Physiol Gastrointest Liver Physiol (2013) 0.77
New treatment options for chronic constipation: mechanisms, efficacy and safety. Can J Gastroenterol (2011) 0.77
Irritable bowel syndrome: new insights into symptom mechanisms and advances in treatment. F1000Res (2016) 0.77
Current developments in pharmacological therapeutics for chronic constipation. Acta Pharm Sin B (2015) 0.77
Novel pharmacological therapies for management of chronic constipation. J Clin Gastroenterol (2014) 0.76
Altered bile acid pool using IBAT inhibitors for constipation: a potentially increased risk of malignancy. Am J Gastroenterol (2012) 0.76
New and emerging therapies for the treatment of irritable bowel syndrome: an update for gastroenterologists. Therap Adv Gastroenterol (2016) 0.76
[To cast out devils by Beelzebub?]. Z Gastroenterol (2012) 0.75
Early investigational therapeutics for gastrointestinal motility disorders: from animal studies to Phase II trials. Expert Opin Investig Drugs (2015) 0.75
Toxic bile and sclerosing cholangitis: Is there a role for pharmacological interruption of the bile acid enterohepatic circulation? Hepatology (2016) 0.75
Turning classical bile acid physiology into everyday pharmacology: impact of a bile acid transporter inhibitor on chronic constipation. Gastroenterology (2012) 0.75
Recent Updates on the Treatment of Constipation. Intest Res (2015) 0.75
Treatment of Chronic Constipation: Prescription Medications and Surgical Therapies. Gastroenterol Hepatol (N Y) (2015) 0.75
Specific inhibition of bile acid transport alters plasma lipids and GLP-1. BMC Cardiovasc Disord (2015) 0.75
Chronic constipation in the elderly: a primer for the gastroenterologist. BMC Gastroenterol (2015) 0.75
Inhibition of ileal bile acid transporter: An emerging therapeutic strategy for chronic idiopathic constipation. World J Gastroenterol (2015) 0.75
Luminally Acting Agents for Constipation Treatment: A Review Based on Literatures and Patents. Front Pharmacol (2017) 0.75
Intractable Constipation in the Elderly. Curr Treat Options Gastroenterol (2017) 0.75
Functional bowel disorders. Gastroenterology (2006) 20.72
American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected]. Am J Gastroenterol (2009) 12.16
Epidemiology of constipation in North America: a systematic review. Am J Gastroenterol (2004) 4.89
Detection of pseudodiarrhoea by simple clinical assessment of intestinal transit rate. BMJ (1990) 2.86
Chronic constipation: a survey of the patient perspective. Aliment Pharmacol Ther (2007) 2.79
Cholestyramine treatment of diarrhea associated with ileal resection. N Engl J Med (1969) 2.40
An epidemiological survey of constipation in canada: definitions, rates, demographics, and predictors of health care seeking. Am J Gastroenterol (2001) 2.30
Functional gastrointestinal disorders as a public health problem. Neurogastroenterol Motil (2008) 2.25
Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function. Clin Gastroenterol Hepatol (2009) 1.87
American Gastroenterological Association Medical Position Statement: guidelines on constipation. Gastroenterology (2000) 1.74
Efficacy of linaclotide for patients with chronic constipation. Gastroenterology (2010) 1.71
Bile acids in the diarrhoea of ileal resection. Gut (1973) 1.68
Effect of molecular structure on bile acid-induced alterations in absorptive function, permeability, and morphology in the perfused rabbit colon. J Lab Clin Med (1979) 1.57
Bile acid synthesis in humans has a rapid diurnal variation that is asynchronous with cholesterol synthesis. Gastroenterology (2005) 1.53
Bile acids and colonic motility in the rabbit and the human. Gut (1975) 1.53
Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis. Gastroenterology (2010) 1.53
The proximal colonic motor response to rectal mechanical and chemical stimulation. Am J Physiol Gastrointest Liver Physiol (2002) 1.38
Effect of tegaserod in chronic constipation: a randomized, double-blind, controlled trial. Clin Gastroenterol Hepatol (2004) 1.27
Bowel disorders. Am J Gastroenterol (2010) 1.23
Altered bile acid metabolism in childhood functional constipation: inactivation of secretory bile acids by sulfation in a subset of patients. J Pediatr Gastroenterol Nutr (2008) 1.21
Taurodeoxycholate modulates apical Cl-/OH- exchange activity in Caco2 cells. Dig Dis Sci (2007) 1.19
Bile acid stimulation of colonic adenylate cyclase and secretion in the rabbit. Am J Dig Dis (1976) 1.19
Bile acids: short and long term effects in the intestine. Scand J Gastroenterol (2010) 1.12
Altered bile acid metabolism in patients with constipation-predominant irritable bowel syndrome and functional constipation. Scand J Gastroenterol (2008) 1.07
Effect of bile acid on anorectal function in man. Gut (1989) 1.03
Bile acids and lipoprotein metabolism: a renaissance for bile acids in the post-statin era? Curr Opin Lipidol (1999) 0.92
Influence of newly synthesized cholesterol on bile acid synthesis during chronic inhibition of bile acid absorption. Hepatology (2003) 0.85
Effect of inhibiting HMG-CoA reductase on 7 alpha-hydroxy-4-cholesten-3-one, a marker of bile acid synthesis: contrasting findings in patients with and without prior up-regulation of the latter pathway. Eur J Clin Invest (1999) 0.84
Functional gastroduodenal disorders. Gastroenterology (2006) 8.51
AGA technical review on irritable bowel syndrome. Gastroenterology (2002) 6.76
Chronic constipation. N Engl J Med (2003) 4.58
Consensus recommendations for gastric emptying scintigraphy: a joint report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine. Am J Gastroenterol (2007) 3.65
A controlled trial of gluten-free diet in patients with irritable bowel syndrome-diarrhea: effects on bowel frequency and intestinal function. Gastroenterology (2013) 3.56
Longitudinal change in perceptual and brain activation response to visceral stimuli in irritable bowel syndrome patients. Gastroenterology (2006) 2.95
Neuroendocrine and neuroimmune markers in IBS: pathophysiological role or epiphenomenon? Gastroenterology (2006) 2.68
Independent influences of body mass and gastric volumes on satiation in humans. Gastroenterology (2004) 2.63
Differences in brain responses to visceral pain between patients with irritable bowel syndrome and ulcerative colitis. Pain (2005) 2.51
Contributions of gastric volumes and gastric emptying to meal size and postmeal symptoms in functional dyspepsia. Gastroenterology (2004) 2.48
Sex-related differences in IBS patients: central processing of visceral stimuli. Gastroenterology (2003) 2.32
Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome. Gastroenterology (2007) 2.30
A study of candidate genotypes associated with dyspepsia in a U.S. community. Am J Gastroenterol (2006) 2.30
Increased bile acid biosynthesis is associated with irritable bowel syndrome with diarrhea. Clin Gastroenterol Hepatol (2012) 2.13
High prevalence of gastroesophageal reflux symptoms and esophagitis with or without symptoms in the general adult Swedish population: a Kalixanda study report. Scand J Gastroenterol (2005) 2.13
The unfolded protein response transducer IRE1α prevents ER stress-induced hepatic steatosis. EMBO J (2011) 2.08
Is irritable bowel syndrome a diagnosis of exclusion?: a survey of primary care providers, gastroenterologists, and IBS experts. Am J Gastroenterol (2010) 2.02
Endogenous hydrogen sulfide regulation of myocardial injury induced by isoproterenol. Biochem Biophys Res Commun (2004) 1.98
Symptomatic overlap between irritable bowel syndrome and microscopic colitis. Inflamm Bowel Dis (2007) 1.97
Contribution of endogenous glucagon-like peptide 1 to glucose metabolism after Roux-en-Y gastric bypass. Diabetes (2013) 1.90
Consensus recommendations for gastric emptying scintigraphy: a joint report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine. J Nucl Med Technol (2008) 1.90
Drawing a blank in functional dyspepsia? Gastroenterology (2006) 1.89
Is a negative colonoscopy associated with reassurance or improved health-related quality of life in irritable bowel syndrome? Gastrointest Endosc (2005) 1.88
Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function. Clin Gastroenterol Hepatol (2009) 1.87
Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol (2003) 1.86
Obesity is associated with increased risk of gastrointestinal symptoms: a population-based study. Am J Gastroenterol (2004) 1.86
Rumination syndrome in children and adolescents: diagnosis, treatment, and prognosis. Pediatrics (2003) 1.76
A community-based, controlled study of the epidemiology and pathophysiology of dyspepsia. Clin Gastroenterol Hepatol (2004) 1.75
Generation of PPARγ mono-allelic knockout pigs via zinc-finger nucleases and nuclear transfer cloning. Cell Res (2011) 1.74
A system model of oral glucose absorption: validation on gold standard data. IEEE Trans Biomed Eng (2006) 1.66
Gastric accommodation and emptying in evaluation of patients with upper gastrointestinal symptoms. Clin Gastroenterol Hepatol (2003) 1.66
The central role of gastrointestinal-specific anxiety in irritable bowel syndrome: further validation of the visceral sensitivity index. Psychosom Med (2007) 1.65
A comparison of visceral and somatic pain processing in the human brainstem using functional magnetic resonance imaging. J Neurosci (2005) 1.60
Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans. Am J Physiol Gastrointest Liver Physiol (2002) 1.58
Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis. Gastroenterology (2010) 1.53
Effect of alginate on satiation, appetite, gastric function, and selected gut satiety hormones in overweight and obesity. Obesity (Silver Spring) (2009) 1.52
Characterization of the alternating bowel habit subtype in patients with irritable bowel syndrome. Am J Gastroenterol (2005) 1.52
Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. Clin Gastroenterol Hepatol (2008) 1.52
Clinical determinants of health-related quality of life in patients with irritable bowel syndrome. Arch Intern Med (2004) 1.51
Irritable bowel syndrome patients show enhanced modulation of visceral perception by auditory stress. Am J Gastroenterol (2003) 1.50
Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes. Diabetes (2007) 1.47
Linaclotide, a synthetic guanylate cyclase C agonist, for the treatment of functional gastrointestinal disorders associated with constipation. Expert Rev Gastroenterol Hepatol (2011) 1.47
Gastric sensory and motor dysfunction in adolescents with functional dyspepsia. J Pediatr (2005) 1.46
Developing irritable bowel syndrome guidelines through meta-analyses: does the emperor really have new clothes? Gastroenterology (2009) 1.43
Prevalence of irritable bowel syndrome among university students: the roles of worry, neuroticism, anxiety sensitivity and visceral anxiety. J Psychosom Res (2003) 1.40
A nutrient drink test to assess maximum tolerated volume and postprandial symptoms: effects of gender, body mass index and age in health. Neurogastroenterol Motil (2002) 1.39
Alterations in mucosal immunity identified in the colon of patients with irritable bowel syndrome. Clin Gastroenterol Hepatol (2008) 1.39
Gastric sensorimotor functions and hormone profile in normal weight, overweight, and obese people. Gastroenterology (2006) 1.39
Urine sugars for in vivo gut permeability: validation and comparisons in irritable bowel syndrome-diarrhea and controls. Am J Physiol Gastrointest Liver Physiol (2011) 1.38
The HIPAA authorization form and effects on survey response rates, nonresponse bias, and data quality: a randomized community study. Med Care (2007) 1.37
Relationship between clinical features and gastric emptying disturbances in diabetes mellitus. Clin Endocrinol (Oxf) (2008) 1.37
Is there an association between GNbeta3-C825T genotype and lower functional gastrointestinal disorders? Gastroenterology (2006) 1.35
Predictors of patient-assessed illness severity in irritable bowel syndrome. Am J Gastroenterol (2008) 1.35
Association between early adverse life events and irritable bowel syndrome. Clin Gastroenterol Hepatol (2011) 1.35
Nitro-oleic acid inhibits angiotensin II-induced hypertension. Circ Res (2010) 1.34
Childhood trauma is associated with hypothalamic-pituitary-adrenal axis responsiveness in irritable bowel syndrome. Gastroenterology (2009) 1.33
Effects of A3309, an ileal bile acid transporter inhibitor, on colonic transit and symptoms in females with functional constipation. Am J Gastroenterol (2011) 1.33
Effect of daikenchuto (TU-100) on gastrointestinal and colonic transit in humans. Am J Physiol Gastrointest Liver Physiol (2010) 1.32
Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease. Clin Gastroenterol Hepatol (2005) 1.29
Do fluctuations in ovarian hormones affect gastrointestinal symptoms in women with irritable bowel syndrome? Gend Med (2009) 1.28
The effect of life stress on symptoms of heartburn. Psychosom Med (2004) 1.28
PPARs and the cardiovascular system. Antioxid Redox Signal (2009) 1.28
Determination of gastric emptying in nonobese diabetic mice. Am J Physiol Gastrointest Liver Physiol (2007) 1.28
Dietary fiber supplements: effects in obesity and metabolic syndrome and relationship to gastrointestinal functions. Gastroenterology (2009) 1.27
Do corticotropin releasing factor-1 receptors influence colonic transit and bowel function in women with irritable bowel syndrome? Am J Physiol Gastrointest Liver Physiol (2009) 1.24
A new model for dermatitis herpetiformis that uses HLA-DQ8 transgenic NOD mice. J Clin Invest (2004) 1.23
Sex-based differences in gastrointestinal pain. Eur J Pain (2004) 1.23
High body mass alters colonic sensory-motor function and transit in humans. Am J Physiol Gastrointest Liver Physiol (2008) 1.22
A Klothoβ variant mediates protein stability and associates with colon transit in irritable bowel syndrome with diarrhea. Gastroenterology (2011) 1.22
Dipeptidyl peptidase-4 inhibition by vildagliptin and the effect on insulin secretion and action in response to meal ingestion in type 2 diabetes. Diabetes Care (2008) 1.20
Phenotypic variation of colonic motor functions in chronic constipation. Gastroenterology (2009) 1.20
Bowel functions, fecal unconjugated primary and secondary bile acids, and colonic transit in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol (2013) 1.20
Liver-enriched transcription factor CREBH interacts with peroxisome proliferator-activated receptor α to regulate metabolic hormone FGF21. Endocrinology (2014) 1.18
Selective effects of serotonergic psychoactive agents on gastrointestinal functions in health. Am J Physiol Gastrointest Liver Physiol (2003) 1.17
Toll-like receptor-mediated IRE1α activation as a therapeutic target for inflammatory arthritis. EMBO J (2013) 1.15
Gastroparesis: clinical update. Am J Gastroenterol (2006) 1.15
Effects of a cannabinoid receptor agonist on colonic motor and sensory functions in humans: a randomized, placebo-controlled study. Am J Physiol Gastrointest Liver Physiol (2007) 1.14
Challenges to the therapeutic pipeline for irritable bowel syndrome: end points and regulatory hurdles. Gastroenterology (2008) 1.14
Diagnosis and management of IBS. Nat Rev Gastroenterol Hepatol (2010) 1.14
Effects of a kappa-opioid agonist, asimadoline, on satiation and GI motor and sensory functions in humans. Am J Physiol Gastrointest Liver Physiol (2003) 1.13
Methods for diagnosis of bile acid malabsorption in clinical practice. Clin Gastroenterol Hepatol (2013) 1.12
Psychometric evaluation of patient-reported outcomes in irritable bowel syndrome randomized controlled trials: a Rome Foundation report. Gastroenterology (2009) 1.11
Irritable bowel syndrome: current approach to symptoms, evaluation, and treatment. Gastroenterol Clin North Am (2007) 1.09
Effect of CCK-1 antagonist, dexloxiglumide, in female patients with irritable bowel syndrome: a pharmacodynamic and pharmacogenomic study. Am J Gastroenterol (2005) 1.09
Gastrointestinal and psychological mediators of health-related quality of life in IBS and IBD: a structural equation modeling analysis. Am J Gastroenterol (2011) 1.09
Effect of a chloride channel activator, lubiprostone, on colonic sensory and motor functions in healthy subjects. Am J Physiol Gastrointest Liver Physiol (2008) 1.09
Effects of venlafaxine, buspirone, and placebo on colonic sensorimotor functions in healthy humans. Clin Gastroenterol Hepatol (2003) 1.08
Cannabinoids in intestinal inflammation and cancer. Pharmacol Res (2009) 1.08
Utility of the Rome I and Rome II criteria for irritable bowel syndrome in U.S. women. Am J Gastroenterol (2002) 1.08
Effect of alvimopan and codeine on gastrointestinal transit: a randomized controlled study. Clin Gastroenterol Hepatol (2005) 1.08
The gastrointestinal tract and glucose tolerance. Curr Opin Clin Nutr Metab Care (2004) 1.07
Effect of gastric volume or emptying on meal-related symptoms after liquid nutrients in obesity: a pharmacologic study. Clin Gastroenterol Hepatol (2005) 1.07
Condition-specific deactivation of brain regions by 5-HT3 receptor antagonist Alosetron. Gastroenterology (2002) 1.05
A stable isotope breath test with a standard meal for abnormal gastric emptying of solids in the clinic and in research. Clin Gastroenterol Hepatol (2008) 1.05
Efficacy of on-demand asimadoline, a peripheral kappa-opioid agonist, in females with irritable bowel syndrome. Clin Gastroenterol Hepatol (2007) 1.04
Regional colon transit in patients with dys-synergic defaecation or slow transit in patients with constipation. Gut (2011) 1.04
Gastric motor and sensory functions in obesity. Obes Res (2005) 1.04
Methods for measurement of gastric motility. Am J Physiol Gastrointest Liver Physiol (2009) 1.03
A controlled pharmacogenetic trial of sibutramine on weight loss and body composition in obese or overweight adults. Gastroenterology (2008) 1.03